Literature DB >> 9181499

Results of an operative policy in the treatment of periprosthetic femoral fracture.

G J McLauchlan1, C M Robinson, B R Singer, J Christie.   

Abstract

OBJECTIVE: To determine the clinical outcome of patients with periprosthetic femoral fractures treated operatively.
DESIGN: Retrospective analysis from 1986 to 1993.
SETTING: Edinburgh Orthopaedic Trauma Unit, Edinburgh, Scotland. PATIENTS: Forty-five patients identified from a computer database as being admitted to the Edinburgh Orthopaedic Trauma Unit with periprosthetic femoral fractures. MAIN OUTCOME MEASURES: Clinical outcome grade (good, fair, poor) dependent on integrity of fixation, refracture rate, and ability to perform activities of daily living analyzed against age, type of fracture, prosthetic alignment, loosening, and method of fixation.
RESULTS: Type I fractures were more common in uncemented or loosely cemented prostheses, whereas type II fractures occurred predominantly in securely cemented prostheses. Type I fractures treated by revision had the poorest results. Outcome in type II fractures was equally good whether treated by internal fixation or by revision. Age, loosening, and prosthetic alignment did not influence outcome. The mortality rate in this series was 20%.
CONCLUSIONS: If a prosthesis is loose, it should be revised, or treatment varies with fracture and prosthetic type. In type I fractures, an uncemented stem may be revised to a cemented one; however, a securely cemented prosthesis probably is better when fixed internally. Type II fractures should be fixed internally because there is less operative insult. Type III fractures probably are not related to the prosthesis and should be fixed internally according to normal practice. The results of an operative policy compare well with the results of conservative management and avoid the problems of long-term immobilization.

Entities:  

Mesh:

Year:  1997        PMID: 9181499     DOI: 10.1097/00005131-199704000-00006

Source DB:  PubMed          Journal:  J Orthop Trauma        ISSN: 0890-5339            Impact factor:   2.512


  8 in total

1.  [Periprosthetic fractures in patients with rheumatoid arthritis].

Authors:  G Pap; H W Neumann
Journal:  Z Rheumatol       Date:  2007-02       Impact factor: 1.372

2.  [Results and complications in the treatment of periprosthetic femur fractures with a locked plate system].

Authors:  J Pressmar; F Macholz; W Merkert; F Gebhard; U C Liener
Journal:  Unfallchirurg       Date:  2010-03       Impact factor: 1.000

3.  Periprosthetic fractures in total hip arthroplasty: an epidemiologic study.

Authors:  Roope Sarvilinna; Heini S A Huhtala; Timo J S Puolakka; Juha K Nevalainen; K Jorma J Pajamäki
Journal:  Int Orthop       Date:  2003-07-30       Impact factor: 3.075

4.  [The prosthesis nail -- a new stable fixation device for periprosthetic fractures and critical fractures of the proximal femur].

Authors:  A Probst; T Schneider; S Hankemeier; E Brug
Journal:  Unfallchirurg       Date:  2003-09       Impact factor: 1.000

Review 5.  Post-operative peri-prosthetic fracture rates following the use of cemented polished taper-slip stems for primary total hip arthroplasty: a systematic review.

Authors:  Kwaku Baryeh; David H Sochart
Journal:  Arch Orthop Trauma Surg       Date:  2022-01-20       Impact factor: 3.067

6.  Periprosthetic femoral fractures in Northern Ireland.

Authors:  A L Ruiz; N W Thompson; J G Brown
Journal:  Ulster Med J       Date:  2000-11

7.  Cement-in-cement stem revision for Vancouver type B periprosthetic femoral fractures after total hip arthroplasty. A 3-year follow-up of 23 cases.

Authors:  Toby W Briant-Evans; Darmaraja Veeramootoo; Eleftherios Tsiridis; Matthew J Hubble
Journal:  Acta Orthop       Date:  2009-10       Impact factor: 3.717

8.  Periprosthetic Fractures About the Hip: A Case-Matched Retrospective Analysis of Functional Outcomes Postrehabilitation.

Authors:  J Tristan Cassidy; Joseph F Baker; Peter Keogh; Paddy Kenny
Journal:  Geriatr Orthop Surg Rehabil       Date:  2015-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.